Joseph O’Connell

Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin.

Mark G. Kris, Richard J. Gralla, R A Clark et al. · Journal of Clinical Oncology · 1985 · 341 citations

Cisplatin Administration, High-dose Cisplatin, Medicine +9

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors

Mark G. Kris, D. Ross Camidge, Giuseppe Giaccone et al. · Annals of Oncology · 2015 · 323 citations · Full text

Her2 Aberrations, Lung Cancers, Oncology +10

Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

Suresh S. Ramalingam, Fiona Blackhall, Maciej Krzakowski et al. · Journal of Clinical Oncology · 2012 · 265 citations · Full text

Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy.

Joseph O’Connell, Mark G. Kris, Richard J. Gralla et al. · Journal of Clinical Oncology · 1986 · 241 citations

Advanced Nsclc, Combination Chemotherapy, Medicine +12

A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib

Karen L. Reckamp, Giuseppe Giaccone, D. Ross Camidge et al. · Cancer · 2014 · 142 citations · Full text